Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

INSPIRE

Financiado

Cerrado

Developing novel inhaled bioengineered Extracellular Vesicle RNA based advanced...

Developing novel inhaled bioengineered Extracellular Vesicle RNA based advanced therapeutics, delivered by tailored aerosol delivery technology for the treatment of lung cancer Lung cancer (LC) treatments have advanced in recent years with the advent of genetic profiling and immunotherapy. However, LC is a complex heterogeneous disease and survival rates remain poor. RNA (mRNA, microRNA, other non-coding... ver más

31/05/2025

MYRIAD CONSULTING

13M€

Presupuesto del proyecto: 13M€

Líder del proyecto

MYRIAD CONSULTING LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-06-01

HORIZON-HLTH-2021-TOOL-06-03: Innovative tools for use and re-use... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 3 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

MYRIAD CONSULTING

Lider

Proyectos interesantes

INSPIRE

Medical Technol...

Biotechnology

13M€ Cerrado

BREATHE

Medical Technol...

Biotechnology

1M€ Cerrado

VECTORES LENTIVIRALES MULTIRREGULABLES PARA I...

Medical Technol...

Biotechnology

291K€ Cerrado

ENDOSCAPE

Medical Technol...

Biotechnology

7M€ Cerrado

PID2020-114356RB-I00

Medical Technol...

Nanotechnology

213K€ Cerrado

EQC2019-006475-P

Medical Technol...

Biotechnology

415K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 35 meses Fecha Inicio: 2022-06-01
Fecha Fin: 2025-05-31

Líder del proyecto

MYRIAD CONSULTING LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 13M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Lung cancer (LC) treatments have advanced in recent years with the advent of genetic profiling and immunotherapy. However, LC is a complex heterogeneous disease and survival rates remain poor. RNA (mRNA, microRNA, other non-coding RNAs and nucleic acid based modulators of same) and gene therapies (DNA or gene editing) for delivering nucleic acid-based therapeutics have curative potential for a host of indications previously untreatable. They have yet to enter the mainstream, due to safety concerns and difficulties delivering them efficiently to areas other than the liver, kidney and circulatory system. Aerosol delivery allows direct targeting of lung tissues but viscous mucus in the lung is a significant barrier to gene transfer to the target cells of the lungs. Even if the mucus layer can be penetrated, inefficient penetration through the cell membrane further impedes access of these vectors to the underlying target cells, thus preventing successful gene transfer. Delivery is a major barrier to successful pulmonary gene therapy for competing viral and non-viral gene transfer vectors and the vast promise of gene therapy has many challenges to overcome. OMNI's novel solution is pioneering the use of genetically modified MSC EVs with a proprietary surface engineering technology to further enhance delivery through the mucus barrier and into the targeted lung cells. This platform technology also combines efficient aerosol delivery of the EVs via AERO's proprietary state of the art vibrating mesh nebulizer technology. This unique solution solves the problems associated with lung targeted delivery of RNA based advanced therapies.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores